Anti-BTN3A Agonistic Monoclonal Antibody ICT01
Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline
Ipsen; ImCheck Therapeutics; acquisition; €350 million; €1 billion deal; immunotherapy; oncology pipeline; butyrophilin superfamily; ICT01; acute myeloid leukemia; monoclonal antibody; BTN3A